" class="no-js "lang="en-US"> Pill Connect secures £0.5m to take electronic smart pill bottle that monitors patient adherence to commercial launch - Medtech Alert
Monday, February 26, 2024

Pill Connect secures £0.5m to take electronic smart pill bottle that monitors patient adherence to commercial launch

Pill Connect, formerly known as Elucid mHealth, has completed a £510,000 funding round with the support of the serial entrepreneur Jonathan Milner, Catapult Ventures and Shallcross Partners. The capital raised will enable Pill Connect to complete development of the design, electronics and software for submission to the regulatory authorities in both Europe and the US and continue through to commercial launch. Pill Connect, was developed to prompt patients to take their medications on time and to send a report back to the doctor to advise them of their patient’s adherence record. The prompt comes from an app on their mobile phone which when acknowledged dispenses a pill or capsule from the bottle through the dispensing cap. Should the patient not wish to take their medication due to illness or an adverse reaction they can respond through the app.

What is unique about the Pill Connect system, as well as providing a detailed adherence record, is that it allows for an immediate intervention by an automated notifications or phone call should the app not be activated. This is particularly important in clinical trials where poor adherence can compromise the validity of the trial. It is well known that compliance rapidly declines over time and in longer studies, especially lasting longer than nine months, adherence drops off a cliff.

The Pill Connect system allows monitors to not only know when that happens but to have the opportunity to intervene and talk to the person in real time, to assess what can be done to help them become more compliant. The monitor has access to a complete dashboard covering the whole trial so that everyone involved can be advised in real time of the rate of compliance or issues which effect adherence. Figures from the OECD (OECD Health Working Paper No.105) shows that poor adherence contributes to nearly 200,000 premature deaths in Europe per year, with an estimated cost EU125 billion – $105 billion in the US – in avoidable hospitalisations, emergency care, and outpatient visits .

The Pill Connect system has already undergone several very successful placebo trials which have proven the robustness of the system, the ability to influence better compliance in real time and frictionless patient acceptance. The system continues to be trialled by both CROs, and major pharma companies who have found that the ability of the system to interact in real time differentiates it from many other products in development. The Pill Connect dispenser mechanism and electronics are designed to fit as a cap onto a standard pill bottle. The capacity of the pill bottle will depend upon the pill size but will have a minimum of thirty pills. The dispensing mechanism can be adjusted to handle pills or capsules of different sizes.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more
More On